

<sup>1</sup>Apoorvi Chaudhri\*, <sup>2</sup>Yunfei Wang, <sup>3</sup>Shao-Hsi Hung, <sup>3</sup>Gregory Lizee, <sup>4</sup>Ulrich Von Andrian, <sup>2</sup>Patrick Hwu, <sup>5</sup>Gordon Freeman. <sup>1</sup>Dana-Farber Cancer Institute, Boston, MA, USA; <sup>2</sup>MD Anderson Cancer Center, Houston, TX, USA; <sup>2</sup>Moffitt Cancer Center, Tampa, FL, USA; <sup>3</sup>MD Anderson Cancer Center, Houston, TX, USA; <sup>4</sup>Harvard Medical School, Boston, MA, USA; <sup>5</sup>Dana-Farber Cancer Institute, Boston, MA, USA

**Background** Cancer has chronic antigen exposure that results in a suppressed CD8 T cell state termed exhaustion. An outcome of anti PD-1 blockade therapy is the expansion of early exhausted CD8+ T cells into a terminally differentiated exhausted state. The reversal of this transcriptionally plastic yet epigenetically fixed state of CD8 T cell exhaustion has the potential to increase responses to anti PD-1 therapy.

**Methods** CX3CR1 is a marker of CD8 T cell activation, effector function however less is known about the contribution of CX3CR1 in CD8 T cell exhaustion. We identified three distinct subsets of CD8+ tumor infiltrating lymphocytes (TILs) based on high, mid, and negative CX3CR1 expression in a mouse model of colon carcinoma.

**Results** The CX3CR1 high CD8+ T cells are more exhausted with higher PD1+TIM3+ expression compared to CX3CR1 mid and CX3CR1 negative cells thereby representing the terminal state of CD8 T cell exhaustion. Moreover, CX3CR1 high CD8 T cells increase following anti PD-1 blockade, and their abundance is associated with a positive response to anti PD-1.

**Conclusions** We identify a consequence of CX3CR1 in terminal T cell exhaustion, and our work can offer strategies to increase responses to anti PD-1.

**Ethics Approval** Animal experiments were performed as per the IACUC regulations at the Dana Farber cancer Institute, and the MD Anderson Cancer Center

<http://dx.doi.org/10.1136/jitc-2021-SITC2021.229>